Micrazym (Amylase, Lipase, Protease)

The three enzymes in Micrazym act in the gastrointestinal tract: amylase hydrolyzes starches into sugars, lipase splits triglycerides into fatty acids and monoglycerides, and protease cleaves proteins into peptides and amino acids. By supplying these enzymes externally, Micrazym compensates for the deficient pancreatic output in affected patients.

The appropriate dose of Micrazym is determined by the prescribing healthcare professional based on the individual’s degree of pancreatic insufficiency, dietary fat content and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Micrazym in pregnancy and lactation are limited. The decision to use the product should be made by a qualified healthcare provider after weighing the potential benefits for the mother against any possible risks to the fetus or infant.

To request Micrazym, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Micrazym contains a combination of amylase, lipase and protease, similar to many standard pancreatic enzyme preparations. Its distinguishing features are the specific enzyme ratios and the EU‑origin manufacturing standards. Clinical effectiveness depends on appropriate dosing and patient adherence, which are comparable across reputable enzyme products.

Micrazym should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, excessive heat and direct sunlight to maintain enzyme stability. Do not refrigerate or freeze unless the label specifically advises otherwise.

Micrazym is taken orally, usually with meals or snacks that contain fat, protein and carbohydrate. The tablets or capsules should be swallowed whole with water unless the prescribing information indicates a different method, such as sprinkling on soft food for patients with swallowing difficulties.

Serious risks, although rare, include allergic reactions that may progress to anaphylaxis, severe abdominal pain indicating possible pancreatitis exacerbation, and persistent vomiting leading to dehydration. Patients should seek immediate medical attention if they experience any of these symptoms.

Micrazym should not be used by individuals with a known hypersensitivity to any of its enzyme components or excipients. It is also contraindicated in patients with active gastrointestinal obstruction or severe acute pancreatitis until the underlying condition is resolved.